ClobazamThird Party Manufacturing in India

Clobazam works by potentiating GABAergic neurotransmission in the central nervous system. It binds to the benzodiazepine site of the GABA-A receptor complex, acting as a positive allosteric modulator that increases the affinity of the receptor for gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the brain. This binding enhances chloride ion conductance through the ionophore, leading to hyperpolarization of the neuronal membrane and reduced neuronal excitability.

Unlike classical 1,4-benzodiazepines, clobazam is a 1,5-benzodiazepine with a distinct pharmacological profile. It has lower affinity for the alpha-1 subunit of the GABA-A receptor, which is primarily responsible for sedative effects, and higher affinity for the alpha-2 subunit, which mediates anxiolytic and anticonvulsant activity. This selectivity results in effective seizure control with comparatively less sedation. The major active metabolite, N-desmethylclobazam (norclobazam), has a longer half-life than the parent compound and contributes significantly to the sustained anticonvulsant effect. Clobazam is metabolized primarily via CYP2C19 and CYP3A4 enzymes in the liver.

Clobazam is a broad-spectrum anticonvulsant and anxiolytic agent primarily used in the management of epilepsy and anxiety disorders.

• Lennox-Gastaut Syndrome: Approved as adjunctive therapy for seizures associated with this severe childhood-onset epilepsy, particularly drop attacks and tonic-clonic seizures.
• Refractory Epilepsy: Used as add-on therapy in patients with treatment-resistant partial and generalized seizures who are not adequately controlled with monotherapy.
• Anxiety Disorders: Effective for acute and chronic anxiety states presenting with tension, restlessness, irritability, and sleep disturbances of emotional origin.
• Dravet Syndrome: Used in combination with stiripentol and valproate for refractory generalized tonic-clonic seizures.
• Status Epilepticus: Employed in intermittent prophylactic treatment protocols for recurrent seizure clusters.

Clobazam is an important molecule in the neurological segment of the Indian pharmaceutical market. It is manufactured primarily in tablet form (5mg, 10mg, and 20mg strengths) and has growing demand from both PCD franchise networks and institutional hospital supplies. Indian manufacturers with WHO-GMP certification supply clobazam to regulated markets across Asia, Africa, and Latin America, where it is valued for its favourable safety profile and reduced sedative burden compared with traditional benzodiazepines. The molecule's inclusion in the WHO Essential Medicines List further underpins its stable demand in the public health sector.